2018年 第12卷 第4期
《医学前沿（英文）》 >> 2018年 第12卷 第4期 doi: tzg@ustc.edu.cn
Challenges of NK cell-based immunotherapy in the new era
1. Institute of Immunology and the CAS Key Laboratory of Innate Immunity and Chronic Disease, Innovation Center for Cell Signaling Network, School of Life Sciences and Medical Center, University of Science and Technology of China, Hefei 230027, China.
2. Hefei National Laboratory for Physical Sciences at Microscale, Hefei 230027, China
下一篇 上一篇
摘要
Natural killer cells (NKs) have a great potential for cancer immunotherapy because they can rapidly and directly kill transformed cells in the absence of antigen presensitization. Various cellular sources, including peripheral blood mononuclear cells (PBMCs), stem cells, and NK cell lines, have been used for producing NK cells. In particular, NK cells that expanded from allogeneic PBMCs exhibit better efficacy than those that did not. However, considering the safety, activities, and reliability of the cell products, researchers must develop an optimal protocol for producing NK cells from PBMCs in the manufacture setting and clinical therapeutic regimen. In this review, the challenges on NK cell-based therapeutic approaches and clinical outcomes are discussed.
京公网安备 11010502051620号
